A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3
A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3
The primary objective of this study is to assess the efficacy of Debio 1347 in terms of objective response rate (ORR) in participants with solid tumors harboring fibroblast growth factor receptor (FGFR)1-3 gene fusion/rearrangement.
Inclusion Criteria:
Exclusion Criteria:
Columbus, Ohio 43210, United States
São Paulo, 01246-000, Brazil
Bordeaux, 33075, France
Lørenskog, 1478, Norway
Ermita, 1000, Philippines
Poznan, 60-355, Poland
Gyeonggi-do, 13605, South Korea
Incheon, 21565, South Korea
Dnipro, 49102, Ukraine
Kharkiv, 61018, Ukraine